Abstract
AbstractThe aim of this work was to design and synthesize a radioiodinated peptide containing arginine–arginine–leucine (RRL) functionality as a potential imaging agent of tumor angiogenesis. The RRL peptide was synthesized using the Fmoc solid phase method and identified by MS analysis after purification by HPLC. The RRL peptide was labeled with 131I by the Chloramine‐T method and purified through Sephadex G‐25 column. Furthermore, the 131I labeled peptide was used to evaluate its biodistribution. SPECT imaging was carried out at 24 h after the 131I labeled RRL peptide was injected into BALB/c nude mice bearing human prostate carcinoma. For the first time we have shown that a radiolabelled RRL peptide appears to be useful as a tumor angiogenic endothelium imaging agent for the diagnosis of the human prostate carcinoma. Copyright © 2008 John Wiley & Sons, Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.